Apimeds Pharmaceuticals US, Inc. (APUS) — Institutional Holders, Q2 2026
7 institutional investment managers reported a APUS position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $383.7K. Every filer is listed below, ranked by position value. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.
APUS in Q2 2026: what funds did
Funds that filed a 13F for both Q1 2026 and Q2 2026, by what they did with the common stock. Share counts are adjusted for any split between the two quarters; dollar figures are the change in shares at this quarter’s price.
Biggest buyers
- JANE STREET GROUPNew · +15,993 sh+$14.4K
- UBS Group AGAdded · +7,631 sh+$6.9K
- Tower Research Capital (TRC)New · +1,664 sh+$1.5K
Biggest sellers
- VANGUARD CAPITAL MANAGEMENTTrimmed · -32,275 sh-$29.0K
- TWO SIGMA SECURITIESSold out · -10,550 sh-$9.5K
- GEODE CAPITAL MANAGEMENTTrimmed · -4,937 sh-$4.4K
APUS 13F holders ranked 1–7 of 7
| # | Institution | Shares | Value | % of portfolio | QoQShares vs Q1 2026 |
|---|---|---|---|---|---|
| 1 | Hemenway#1 · 274,000 sh | 274,000 | $246.6K | 0.02% | 0.0% |
| 2 | VANGUARD CAPITAL MANAGEMENT#2 · 63,654 sh | 63,654 | $57.3K | 0.00% | -33.6% |
| 3 | GEODE CAPITAL MANAGEMENT#3 · 35,114 sh | 35,114 | $31.6K | 0.00% | -12.3% |
| 4 | VANGUARD FIDUCIARY#4 · 24,039 sh | 24,039 | $21.6K | 0.00% | 0.0% |
| 5 | JANE STREET GROUP#5 · 15,993 sh | 15,993 | $14.4K | 0.00% | New |
| 6 | UBS Group AG#6 · 11,818 sh | 11,818 | $10.6K | 0.00% | +182.3% |
| 7 | Tower Research Capital (TRC)#7 · 1,664 sh | 1,664 | $1.5K | 0.00% | New |
Funds that sold out of APUS in Q2 2026 (1)
Held APUS at the end of Q1 2026 and filed a Q2 2026 13F without it. Not in the list above, because they no longer hold it. Largest prior position first.
| Institution | Shares sold | Value in Q1 2026 |
|---|---|---|
| TWO SIGMA SECURITIES10,550 sh | 10,550 | $18.9K |
Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.